ANG Lifesciences India Limited (BOM:540694)
India · Delayed Price · Currency is INR 40.27
+0.78 (1.98%)
At close: Sep 25, 2026
ANG Lifesciences India Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 835.87 | 928.93 | 928.47 | 1,461 | 2,199 | 3,543 |
Other Revenue | 0 | - | 0 | - | - | - |
| 835.87 | 928.93 | 928.47 | 1,461 | 2,199 | 3,543 | |
Revenue Growth | -15.60% | 0.05% | -36.45% | -33.55% | -37.94% | 129.50% |
Cost of Revenue | 561.73 | 619.76 | 596.23 | 951.13 | 1,506 | 2,280 |
Gross Profit | 274.14 | 309.17 | 332.24 | 509.97 | 693.01 | 1,263 |
Selling, General & Admin | 164.61 | 168.95 | 178.11 | 196.85 | 243.32 | 214.77 |
Other Operating Expenses | 122.89 | 127.79 | 154.99 | 215.62 | 221.53 | 371.08 |
Operating Expenses | 350.48 | 360.01 | 400.71 | 496.19 | 558.38 | 644.6 |
Operating Income | -76.34 | -50.84 | -68.47 | 13.78 | 134.63 | 618.6 |
Interest Expense | -82.33 | -79.34 | -88.8 | -103.22 | -111.93 | -82.8 |
Interest & Investment Income | 5.12 | 5.12 | 2.26 | 5.28 | 6.46 | 2.9 |
Currency Exchange Gain (Loss) | -5.37 | -5.37 | - | -0.98 | -4.51 | -1.71 |
Other Non Operating Income (Expenses) | 0 | - | 2.47 | -6.35 | -6.85 | -0.93 |
EBT Excluding Unusual Items | -158.91 | -130.43 | -152.54 | -91.49 | 17.81 | 536.07 |
Gain (Loss) on Sale of Assets | 0.32 | 0.32 | -4.5 | 1.71 | 8.44 | -1.06 |
Other Unusual Items | - | - | - | -17.35 | - | - |
Pretax Income | -158.59 | -130.11 | -157.04 | -107.14 | 26.25 | 535.01 |
Income Tax Expense | -25.36 | -19.26 | -32.9 | -5.71 | 28.87 | 131.84 |
Net Income | -133.23 | -110.85 | -124.13 | -101.43 | -2.62 | 403.17 |
Net Income to Common | -133.23 | -110.85 | -124.13 | -101.43 | -2.62 | 403.17 |
Net Income Growth | - | - | - | - | - | 473.69% |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Change | -1.32% | - | - | 0.51% | 0.26% | - |
EPS (Basic) | -10.22 | -8.49 | -9.51 | -7.77 | -0.20 | 31.11 |
EPS (Diluted) | -10.22 | -8.49 | -9.51 | -7.77 | -0.20 | 31.11 |
EPS Growth | - | - | - | - | - | 473.69% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 105.91 | -40.07 | -150.63 | 159.33 | -166.28 |
Free Cash Flow Per Share | - | 8.11 | -3.07 | -11.54 | 12.26 | -12.83 |
Dividend Per Share | - | - | - | - | - | 0.800 |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 32.80% | 33.28% | 35.78% | 34.90% | 31.52% | 35.65% |
Operating Margin | -9.13% | -5.47% | -7.37% | 0.94% | 6.12% | 17.46% |
Profit Margin | -15.94% | -11.93% | -13.37% | -6.94% | -0.12% | 11.38% |
Free Cash Flow Margin | - | 11.40% | -4.32% | -10.31% | 7.25% | -4.69% |
EBITDA | -20.35 | 3.64 | -14.56 | 88.95 | 225.34 | 677.17 |
EBITDA Margin | -2.43% | 0.39% | -1.57% | 6.09% | 10.25% | 19.11% |
D&A For EBITDA | 56 | 54.48 | 53.91 | 75.17 | 90.71 | 58.58 |
EBIT | -76.34 | -50.84 | -68.47 | 13.78 | 134.63 | 618.6 |
EBIT Margin | -9.13% | -5.47% | -7.37% | 0.94% | 6.12% | 17.46% |
Effective Tax Rate | - | - | - | - | 109.99% | 24.64% |
Revenue as Reported | 841.5 | 934.37 | 948.66 | 1,468 | 2,296 | 3,552 |
Advertising Expenses | - | - | - | 0.08 | - | - |